Table 1 Demographic and clinical characteristics for the total sample (n = 41).

From: The mapping of cortical activation by near-infrared spectroscopy might be a biomarker related to the severity of fibromyalgia symptoms

 

Fibromyalgia (n = 22)

Controls (n = 19)

P value

Mean

SD

Mean

SD

Demographic variables

Age (years)

47.14

9.49

34.68

12.45

0.001

Body mass index$

27.83

4.17

23.12

3.37

0.001

Years of study

13.55

2.74

17.29

3.31

< 0.001

Outcome’s variables

Portuguese Profile of Chronic Pain Screen (BP-PCP:S) total score

71.95

15.56

14.11

15.54

< 0.001

BP-PCP:S—severity

25.68

3.24

6.74

6.37

< 0.001

BP-PCP:S—activity

27.50

9.74

4.47

7.43

< 0.001

BP-PCP:S—emotional burden

18.77

5.00

2.89

4.01

< 0.001

Brazilian Portuguese Central Sensitization Inventory (BP-SCI)

71.18

13.72

21.37

11.19

< 0.001

Clinical variables and psychological measures

The American College of Rheumatology (ACR)

 Widespread pain index (WPI)

13.81

22.50

   

 Symptom Severity (SS) Scale

10.58

1.58

   

Beck Depression Inventory (BDI-II) total score

28.45

12.07

7.53

9.39

< 0.001

Strait-Trait Anxiety Inventory—short version (STAI-SV)—State scale

30.00

7.34

22.32

6.48

0.001

Strait-Trait Anxiety Inventory—short version (STAI-SV)—Trait scale$

27.81

3.44

18.11

4.53

< 0.001

Brazilian Pain Catastrophizing Scale (B-PCS) total score

39.27

8.40

7.37

12.57

< 0.001

Medication use

Yes/no

% Yes

Yes/no

% Yes

 

Psychiatric medication use

Benzodiazepine

4/18

18.2

–

–

–

Antidepressant

12/10

54.5

–

–

–

Anticonvulsant

10/12

45.5

–

–

–

Number of days of analgesic use per week in the previous month (< 4 times/> 4 times)

20/2

90.9

–

–

–

  1. SD standard deviation.
  2. All P values are based on Mann–Whitney test, except for “regular analgesic use” which is based on Fisher’s exact test. $ = missing data for FM group with n = 21.
Back to article page